Disclosed is a 2-oxo-1,2-dihydro-quinoline (also known as Laquinimod) compound of formula I, wherein the substituents are independently selected from the group consisting of hydrogen and deuterium, and where at least one substituent is deuterium. Further disclosed is a pharmaceutical composition comprising said compound, and the use of said compound in the manufacture of a medicament for use in treating an immune function mediated disorder.
